HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Causalgia (Syndrome, Causalgia)

A complex regional pain syndrome characterized by burning pain and marked sensitivity to touch (HYPERESTHESIA) in the distribution of an injured peripheral nerve. Autonomic dysfunction in the form of sudomotor (i.e., sympathetic innervation to sweat glands), vasomotor, and trophic skin changes may also occur. (Adams et al., Principles of Neurology, 6th ed, p1359)
Also Known As:
Syndrome, Causalgia; CRPS Type II; Causalgia Syndrome; Deafferentation Pain; Type II Complex Regional Pain Syndrome; Causalgia Syndromes; Pain, Deafferentation; Syndromes, Causalgia; Complex Regional Pain Syndrome Type II
Networked: 285 relevant articles (24 outcomes, 16 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Pain (Aches)
2. Causalgia (Syndrome, Causalgia)
3. Neuralgia (Stump Neuralgia)
4. Reflex Sympathetic Dystrophy (Reflex Sympathetic Dystrophy Syndrome)
5. Chronic Pain

Experts

1. Burchiel, Kim J: 3 articles (01/2011 - 11/2003)
2. Esfahani, Darian R: 2 articles (05/2018 - 01/2011)
3. Aziz, Tipu Z: 2 articles (07/2017 - 09/2013)
4. Chamadoira, Clara: 2 articles (07/2017 - 09/2013)
5. Pereira, Erlick A C: 2 articles (07/2017 - 09/2013)
6. Rebelo, Virgínia: 2 articles (07/2017 - 09/2013)
7. Rosas, Maria José: 2 articles (07/2017 - 09/2013)
8. Vaz, Rui: 2 articles (07/2017 - 09/2013)
9. Sakamoto, Atsuhiro: 2 articles (01/2017 - 08/2003)
10. Agnello, Kimberly: 2 articles (06/2015 - 11/2013)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Causalgia:
1. Lidocaine (Xylocaine)FDA LinkGeneric
01/01/2007 - "From a mechanistic perspective, the hypothesis that the lidocaine patch would be most effective in patients with relatively intact epidermal innervation, whose neuropathic pain is presumed attributable to "irritable nociceptors," and least effective in patients with few surviving epidermal nociceptors, presumably with "deafferentation pain," was unproven. "
03/01/1999 - "Nine patients with Complex Regional Pain Syndrome types I and/or II (CRPS), previously known as reflex sympathetic dystrophy (RSD) and causalgia, respectively, were selected for treatment with a continuous four to eight week subcutaneous infusion of 10% lidocaine. "
12/01/2022 - "This qualitative review found insufficient, heterogenous evidence and therefore no recommendation can be made for lidocaine infusion treatment in patients with chronic neuropathic pain due to spinal cord injury, peripheral nerve injury, diabetic neuropathy, postherpetic neuralgia, or complex regional pain syndrome type II. Larger randomized, double-blind, placebo-controlled studies are required to further establish the efficacy of lidocaine infusion in patients with these etiologies of chronic neuropathic pain."
05/01/1994 - "Deafferentation pain exacerbated by subarachnoid lidocaine and relieved by subarachnoid morphine. "
05/01/2018 - "We compared the efficacy and safety of lidocaine infusions (3 mg/kg) in the LIT group and normal saline infusions in the control group once a week for 4 consecutive weeks in patients with postherpetic neuralgia or complex regional pain syndrome type II. The primary outcome was the difference in the percentage change in the 11-point numerical rating scale (NRS) pain score from baseline to after the final infusion. "
2. Morphine (MS Contin)FDA LinkGeneric
3. GuanethidineFDA Link
4. Clonazepam (Rivotril)FDA LinkGeneric
5. Opioid Analgesics (Opioids)IBA
6. BaclofenFDA LinkGeneric
7. PhenoxybenzamineFDA Link
8. KetamineFDA LinkGeneric
9. Propofol (Diprivan)FDA LinkGeneric
10. Thiopental (Pentothal)FDA Link

Therapies and Procedures

1. Sympathectomy (Sympathectomies)
2. Spinal Cord Stimulation
3. Surgical Amputation (Amputations)
4. Drug Therapy (Chemotherapy)
5. Therapeutics